Phibro Animal Health Stock Forecast, Price & News

Phibro Animal Health (NASDAQ:PAHC) Frequently Asked Questions

Is Phibro Animal Health a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Phibro Animal Health in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Phibro Animal Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PAHC, but not buy additional shares or sell existing shares.
View analyst ratings for Phibro Animal Health or view top-rated stocks.

How has Phibro Animal Health's stock price been impacted by COVID-19?

Phibro Animal Health's stock was trading at $24.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PAHC stock has decreased by 18.8% and is now trading at $19.95.
View which stocks have been most impacted by COVID-19.

When is Phibro Animal Health's next earnings date?

Phibro Animal Health is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Phibro Animal Health.

How can I listen to Phibro Animal Health's earnings call?

Phibro Animal Health will be holding an earnings conference call on Thursday, February 10th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Phibro Animal Health's earnings last quarter?

Phibro Animal Health Co. (NASDAQ:PAHC) announced its quarterly earnings data on Tuesday, November, 2nd. The company reported $0.25 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by $0.04. The firm had revenue of $214.70 million for the quarter. Phibro Animal Health had a net margin of 5.70% and a trailing twelve-month return on equity of 22.34%. During the same quarter in the previous year, the company posted $0.27 EPS.
View Phibro Animal Health's earnings history.

How often does Phibro Animal Health pay dividends? What is the dividend yield for Phibro Animal Health?

Phibro Animal Health declared a quarterly dividend on Monday, November 1st. Stockholders of record on Wednesday, November 24th will be given a dividend of $0.12 per share on Wednesday, December 15th. This represents a $0.48 annualized dividend and a dividend yield of 2.41%. The ex-dividend date is Tuesday, November 23rd.
View Phibro Animal Health's dividend history.

Is Phibro Animal Health a good dividend stock?

Phibro Animal Health pays an annual dividend of $0.48 per share and currently has a dividend yield of 2.42%. The dividend payout ratio of Phibro Animal Health is 40.00%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Phibro Animal Health will have a dividend payout ratio of 35.82% next year. This indicates that Phibro Animal Health will be able to sustain or increase its dividend.
View Phibro Animal Health's dividend history.

What guidance has Phibro Animal Health issued on next quarter's earnings?

Phibro Animal Health issued an update on its FY 2022 earnings guidance on Tuesday, November, 9th. The company provided earnings per share (EPS) guidance of $1.250-$1.320 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.290. The company issued revenue guidance of $860 million-$890 million, compared to the consensus revenue estimate of $860.37 million.

What price target have analysts set for PAHC?

2 equities research analysts have issued 12 month price targets for Phibro Animal Health's stock. Their forecasts range from $23.00 to $23.00. On average, they expect Phibro Animal Health's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 15.3% from the stock's current price.
View analysts' price targets for Phibro Animal Health or view top-rated stocks among Wall Street analysts.

Who are Phibro Animal Health's key executives?

Phibro Animal Health's management team includes the following people:

• Jack C. Bendheim, Chairman, President & Chief Executive Officer
• Larry L. Miller, Chief Operating Officer
• Damian Finio, Chief Financial Officer
• Thomas G. Dagger, Secretary, Senior Vice President & General Counsel
• Mona Desai, Vice President & Controller

What is Jack Bendheim's approval rating as Phibro Animal Health's CEO?

4 employees have rated Phibro Animal Health CEO Jack Bendheim on Glassdoor.com. Jack Bendheim has an approval rating of 100% among Phibro Animal Health's employees. This puts Jack Bendheim in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Phibro Animal Health's key competitors?

Some companies that are related to Phibro Animal Health include Apellis Pharmaceuticals (APLS), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), OPKO Health (OPK), Pacira BioSciences (PCRX), PTC Therapeutics (PTCT), Insmed (INSM), Cytokinetics (CYTK), Zentalis Pharmaceuticals (ZNTL), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD), Mawson Infrastructure Group (WIZP), Sage Therapeutics (SAGE), I-Mab (IMAB) and Indivior (INVVY).
View all of PAHC's competitors.

What other stocks do shareholders of Phibro Animal Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phibro Animal Health investors own include Zynga (ZNGA), Trevena (TRVN), Endo International (ENDP), Sonoma Pharmaceuticals (SNOA), Zynerba Pharmaceuticals (ZYNE), Intercept Pharmaceuticals (ICPT), VIVUS (VVUS), Zoetis (ZTS), Banco Bradesco (BBD) and Booking (BKNG).

What is Phibro Animal Health's stock symbol?

Phibro Animal Health trades on the NASDAQ under the ticker symbol "PAHC."

Who are Phibro Animal Health's major shareholders?

Phibro Animal Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Confluence Investment Management LLC (0.29%), Russell Investments Group Ltd. (0.27%) and Bridge City Capital LLC (0.19%). Company insiders that own Phibro Animal Health stock include E Thomas Corcoran and Larry Lee Miller.
View institutional ownership trends for Phibro Animal Health.

Which major investors are selling Phibro Animal Health stock?

PAHC stock was sold by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC.
View insider buying and selling activity for Phibro Animal Health or view top insider-selling stocks.

Which major investors are buying Phibro Animal Health stock?

PAHC stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., and Bridge City Capital LLC.
View insider buying and selling activity for Phibro Animal Health or or view top insider-buying stocks.

How do I buy shares of Phibro Animal Health?

Shares of PAHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Phibro Animal Health's stock price today?

One share of PAHC stock can currently be purchased for approximately $19.95.

How much money does Phibro Animal Health make?

Phibro Animal Health has a market capitalization of $808.05 million and generates $833.40 million in revenue each year. The company earns $54.38 million in net income (profit) each year or $1.20 on an earnings per share basis.

How many employees does Phibro Animal Health have?

Phibro Animal Health employs 1,725 workers across the globe.

What is Phibro Animal Health's official website?

The official website for Phibro Animal Health is www.pahc.com.

Where are Phibro Animal Health's headquarters?

Phibro Animal Health is headquartered at GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666.

How can I contact Phibro Animal Health?

Phibro Animal Health's mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The company can be reached via phone at (201) 329-7300, via email at [email protected], or via fax at 201-329-7399.